Lene Andersen (Danish, born 1958) joined PILA PHARMA in 2016 as Director of the Board due to her thorough understanding of the diabetes market, its drivers and the positioning of new diabetes drugs.
Lene Andersen provides significant experience to PILA PHARMA within licensing, business strategy & development and project management in the diabetes field obtained through various operational leadership roles in Operations and Corporate Relations during her almost 2 decades at Novo Nordisk, a Danish healthcare company in the diabetes segment.
Lene Andersen holds a BA in Economics from Copenhagen Business School, Denmark from 1989 as well as an MSc in Sustainability and Responsibility from Ashridge Business School in London, United Kingdom from 2012. She is an active member of Keyhaven Capital Partners as well as Connect Denmark’s Advisory Boards.
Lene worked with licensing and business development (1994-2000) after which she in 2001-02 was heading New Product Planning in diabetes and was ensuring integration of business needs into global development projects. She was promoted to Project and Corporate Vice President for the development and marketing of the modern insulin portfolio in 2006-2008. She developed a portfolio strategy for the modern insulins and during that period, 65% of the growth of the company was attributable to the modern insulin portfolio and one of the brands reached a blockbuster status of sales above 1 BUSD. In 2008-2012, she was Vice President in Corporate Relations in charge of the global patient strategy and execution of external partnerships within diabetes.
Since 2012, Lene Andersen has worked as an independent consultant and today she is a partner in Factor3, a Danish management consultancy practice. Furthermore, she brings a comprehensive toolbox from this role, where she is designing and facilitating strategy processes as well as strategy realisation in both private and public organisations.